alexa Cardiac Toxicity Risk Of Long-term Use Of Trastuzumab In Metastatic Breast Cancer-The Importance Of A Cardio-oncology Team | 68383
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

36th Cardiovascular Nursing & Nurse Practitioners Meeting

Cristina Florescu
Craiova University of Medicine and Pharmacy, Romania
ScientificTracks Abstracts: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880-C1-074
Abstract
The prognosis of patients with cancer was substantially improved by early detection and modern treatments, one of these being signalling inhibitors, alone or combined with conventional chemotherapy. Patients receiving cancer therapies may have their quality of life and survival affected by cardiotoxicity, because higher survival rates brings more patients presenting with cardiac adverse effects. Signalling inhibitors like trastuzumab have a risk of cardiovascular adverse effects including cardiac dysfunction and development of heart failure, myocardial ischemia, arrhytmia, QT prolongation, and arterial hypertension. Iatrogenic side effects of these drugs could be irreversible lesions or reversible dysfunction, but exist also the possibility of being overlapped, for example, trastuzumab may produce irreversible cardiac damage in patients with preexisting cardiac dysfunction or augment anthracyclines type I cardiotoxicity. Cardiovascular treatment may delay expression of cardiac dysfunction in these patients. Monitoring the cardiac health of patients before, during and after cancer treatment is very important. It is possible that patients eligibility for cancer therapies may be affected, and also their life expectancy. In some cases, cancer treatments may be stopped without prompt access to cardio-oncology expertise. Also, patients are not eligible for the aggressive treatments needed, remaining a potential risk of being undertreated, having treatment delays or having dose decreased. Trastuzumab, a monoclonal antibody targeted against HER 2 / erb B2 and VEGF (vascular endothelial growth factor) signalling pathways, in combination with chemotherapy improved prognosis of women with HER 2 overexpressed breast cancer. The main concern of long-term therapy with trastuzumab remains its association with potential cardiotoxicity. Although real, cardiac side effects of trastuzumab are probably overemphasized. I report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who was treated with trastuzumab for more than 9 years without significant cardiac toxicity.
Biography

Cristina Florescu is lecturer at Craiova University of Medicine and Pharmacy, senior doctor in cardiology and internal medicine, has a Master degree in Health Services and is Doctor of Medicine. Her domains of interest are heart failure, echocardiography, prevention medicine and cardio-oncology.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7